NEW YORK, March 19, 2018 -- ImmuDyne, Inc. (OTCQB:IMMD) (“Immudyne” or the “Company”), a leader in the development and marketing of OTC healthcare products, is pleased to announce the launch of the INR Wellness immune support product line.
INR Wellness is a once-daily nutritional supplement that contains yeast, oat, and mushroom beta-glucans. These three naturally occurring beta-glucans have been shown across hundreds of clinical studies to support the human immune system and are commonly used as an OTC supplement to reduce cholesterol levels, manage blood glucose levels, and to support the immune system in people whose body defenses have been weakened by conditions such as chronic fatigue, or physical and emotional stress; or by treatments such as radiation or chemotherapy.
Immudyne’s INR Wellness product is the first in the world with a proprietary triple-action formulation that contains what we believe to be the most important beta glucans for overall immune support.
“We’re excited to add another revenue stream to Immudyne’s portfolio,” stated Justin Schreiber, President & CEO of Immudyne. “We believe INR Wellness is the highest quality immune support product on the market and presents a significant growth opportunity for the Company.”
Immudyne will begin sales of INR Wellness on Monday, March 19th, 2018 through the Company’s website. A national Facebook, Google and Amazon campaign will commence shortly thereafter.
“In 2017, the U.S. nutritional supplement and vitamin market was approximately $36.1 billion,” stated Stefan Galluppi, Chief Technology and Operating Officer of Immudyne. “The immune support vertical is an attractive segment of the supplement market that has seen little innovation in recent years. Given the extensive clinical data and proprietary formulation of INR Wellness, we believe we're well positioned for a successful product launch.”
For more information on INR Wellness or to purchase the product, please visit https://www.inrwellness.com/.
About lmmuDyne
lmmuDyne, Inc. (the "Company") is an online direct response marketing company that builds innovative and proprietary health and wellness brands that transform and enrich the lives of consumers around the world. Immudyne’s scalable and global advertising technology infrastructure leverages the world’s largest social media and online sales platforms (Facebook, Google & Amazon) to rapidly and profitably grow our continually expanding product portfolio. To learn more about our corporate strategy, brands or for investor relations please visit www.immudyne.com or email us at [email protected].


Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 



